Plain English coverage of UK weight loss injections including Mounjaro, Wegovy and Ozempic — how they work, NHS access, private clinic costs and real patient experiences.
When the Pharmaceutical Journal reported this week that 3.3 million UK adults are expected to use weight loss jabs in 2026, it marked a genuine turning point. This is no longer a niche private treatment for early adopters. It is becoming one of the most widely used drug classes in modern British medicine. But scale…
A new injectable weight loss medicine called CagriSema UK is generating serious attention among doctors and patients alike. Developed by Novo Nordisk — the same company behind Ozempic and Wegovy — it combines two separate drugs into one weekly injection. Early clinical trial results suggest it could help people lose significantly more weight than any…
If you have heard about weight loss jabs from a friend, seen them on the news, or quietly Googled them at midnight, you are not alone. Millions of UK women are asking the same question right now: is Mounjaro or Ozempic the better choice for me? This development was announced on 1 January 2025, as…
The NHS Mounjaro rollout has entered a significant new phase in England, expanding access to tirzepatide — the active ingredient in Mounjaro — to a broader group of patients. This development was announced on June 2026. According to NHS England and GOV.UK, patients with a BMI of 35 or above who also have at least…
If you have been paying £200 or more a month for Mounjaro out of your own pocket, this week’s news from NHS England deserves your full attention. A new supply and access agreement between NHS England and Eli Lilly — the pharmaceutical company that makes Mounjaro — was confirmed in May 2026. It signals a…